ALIGOS THERAPEUTICS INC (ALGS) Stock Analyst Ratings
NASDAQ:ALGS - Nasdaq - US01626L2043 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 84% to ALGS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 86.96. This target is 1035.18% above the current price.
ALGS was analyzed by 10 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about ALGS.
In the previous month the buy percentage consensus was at a similar level.
ALGS was analyzed by 10 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-31 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-19 | HC Wainwright & Co. | Initiate | Buy |
| 2023-01-17 | Piper Sandler | Maintains | Overweight |
| 2023-01-06 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2023-01-06 | Jefferies | Upgrade | Hold -> Buy |
| 2022-11-03 | SVB Leerink | Maintains | Market Perform |
| 2022-05-05 | SVB Leerink | Downgrade | Outperform -> Market Perform |
| 2022-03-11 | SVB Leerink | Maintains | Outperform |
| 2022-03-11 | Piper Sandler | Maintains | Overweight |
| 2022-02-16 | SVB Leerink | Maintains | Outperform |
| 2022-01-07 | SVB Leerink | Maintains | Outperform |
| 2022-01-07 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2021-09-09 | SVB Leerink | Initiate | Outperform |